Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology.
It’s time we move beyond BMI and adopt a holistic approach to truly gauge health.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
As the innovative, multi-billion dollar industry expands rapidly, pharma companies must consider how to deliver and differentiate.
Opioids are our most effective tool for treating pain, but what if there were a better way to stop pain without relying on addictive substances? To develop a non-addictive painkiller, scientists have been searching for proteins that appear on pain neurons but not in the reward pathway, and this has been no small task.
In response to emailed questions, the CEO and CTO talk about the immune intelligence startup's Human Immunity Map — a growing database of immune interactions that can support the development of multiplex diagnostics, vaccines and therapeutics.